Glaxosmithkline LLC

Duke University

Immunolight, LLC

Smithkline Beecham (cork) Ltd

Gooden, David

Spector, Neil, L.

Xia, Wenle

Toone, Eric, J.

Walder, Harold

Beyer, Wayne, F.

Soderblom, Erik, J.

Wenle Xia

Neil Lee Spector

Karen Elizabeth Lackey

Edgar Raymond Wood, Iii

Harold Walder

Eric John Toone

David M Gooden

Wayne F Beyer, Jr

Robert J Mullin

Erik J Soderblom

Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders

A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

Cancer treatment method

The truncated ErbB2 receptor (p95) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95inhibitor, and methods of treating such patients.

Treatment of cancers expressing p95 ErbB2

A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as pharmaceutical combinations and compositions containing the same.

Growing community of inventors

Durham, NC, United States of America

Wenle Xia